2型糖尿病。
法国羁系法国卫平生安战康健产物委员会(AFSSAPS)于6月9日要求新患者暂停利用艾可拓(Actos)及其复方造剂Competect(匹格列酮/二甲双胍),而目前正正在利用艾可拓的患者应向大夫征询。
基于618个网页-相关网页
该研究由生产艾可拓的武田制药赞助。
The study was funded by Takeda Pharmaceuticals, which manufactures Actos.
艾可拓和亚莫利作用非常不同。艾可拓增强胰岛素敏感性。亚莫利刺激胰腺分泌胰岛素。
Actos and Amaryl work very differently. Actos makes the body more sensitive to insulin. Amaryl stimulates the pancreas to release more insulin.
艾可拓背着一个“黑锅”,警告这种药物可能引起心衰,但是到目前为止并未发现它增加心脏事件的危险性。
Actos carries a "black box" warning that the drug may trigger heart failure, but it has not been linked to any increased risk of heart attack.
应用推荐